JIMOXY-CV 228.5 is a paediatric Amoxicillin-Clavulanate suspension positioned for the management of selected susceptible bacterial infections. The combination provides enhanced antibacterial coverage while the liquid format facilitates convenient and flexible paediatric dosing. A strong PCD Pharma Paediatric Antibiotic portfolio product.
Selected susceptible bacterial infections.
To overcome certain beta-lactamase-mediated resistance.
Confirm penicillin allergy before use. Use only on prescription, complete the course and seek immediate attention for facial swelling, breathing difficulty or severe rash.
Diarrhea, nausea, vomiting, abdominal discomfort and rash may occur; hypersensitivity reactions can be serious.
JIMOXY-CV 228.5: Amoxicillin inhibits bacterial cell-wall synthesis, while Clavulanic Acid inhibits certain beta-lactamases, extending antibacterial activity against susceptible organisms.
